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Introduction
The number of suitable radiometals for use in nuclear medi-
cine (both in diagnosis and in therapy) is considerable (g-
emitters like 111In or 67Ga; positron emitters as 68Ga or 64Cu,
and particle emitters like 90Y, 177Lu (b-emitter) or 213Bi (a-
emitter)).[1–4] However, the central question in the develop-
ment of new radiopharmaceutical agents is how to deliver
them specifically to the cellular targets (receptors). Many
strategies have been attempted and some are currently in
clinical use. The general strategy in the field of gamma-
imaging is based on the use of radio-labeled conjugates that
bind to specific receptors that are overexpressed in certain
regions or organs in the body. Specific carriers like monoclo-
nal antibodies[5] and peptides[6] proved, so far, to be the
most successful approaches. The moiety of the conjugate
that encapsulates the radio metal is a bifunctional chelator
which simultaneously presents a functionality (usually car-
boxylic and amine groups) suitable for covalent binding to
the carrier agent.
Magnetic resonance imaging (MRI) is a diagnostic modal-
ity based on the enhancement of contrast given by paramag-
netic contrast agents (CAs). Gadolinium(iii) chelates dem-
onstrated to be the most suitable paramagnetic CAs for
MRI, due to the high paramagnetism of the GdIII ion (4f7)
and to its slow electron spin relaxation. The efficiency of a
MRI CA is based on its ability to selectively reduce the
water proton relaxation times of normal and lesioned tissues
in the body, and is expressed by its relaxivity, r1 (in units of
mm1 s1). The relaxivity is defined as the longitudinal relax-
ation rate enhancement of the water protons for 1mm con-
centration of paramagnetic compound.[7,8]
Nowadays molecular imaging is a field of fast rising inter-
est.[9] The main requisites in molecular imaging using MRI
are high relaxivity and high biospecificity, in order to deliver
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as many paramagnetic species as possible to the receptors of
interest and thus obtain images of the targeted cells.
For the detection of hepatic lesions there are a few hepa-
tocyte-specific MRI CAs which are lipophilic or amphiphilic
compounds: [Gd(BOPTA)(H2O)]
2 (BOPTA=4-carboxy-
5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-trazatride-
can-13-oic acid),[10] [Gd(EOB-DTPA)(H2O)]
2 (EOB-DTPA
= (S)-N-[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)-
propyl]-N-[2-[bis(carboxymethyl)amino]ethyl]glycine),[11]
[Mn(dpdp)(H2O)] (DPDP = N,N’-1,2-ethanediylbis-[N-[[3-
hydroxy-2-methyl-5-[phosphonooxymethyl]-4-pyridinyl]me-
thyl]glycine]),[12] superparamagnetic iron oxides,[13] liposo-
mal[14] and micellar[15] paramagnetic systems.
The focus of our ongoing research plan is the synthesis of
multivalent glycoconjugates of metal complexes as potential
agents for medical imaging (MRI and scintigraphy). These
compounds include two different moieties: a metal chelator
capable of forming chelates with lanthanide(iii) ions with
high kinetic and thermodynamic stability, and a sugar
moiety capable of interacting with high affinity and selectivi-
ty with endogenous lectins.[16] Lectins are a large group of
carbohydrate binding proteins broadly found in nature (in-
cluding plants, animals and lower organisms). The lectin-car-
bohydrate interaction controls many biological events
(immune function, fertilization, infectious cycles, metastasis,
etc.).[17] The effect of the valence of synthetic and natural
glycoconjugates on the affinity to lectins has been fully dem-
onstrated, although the physical nature of the phenomenon
is still debatable.[18] A critical feature in the glycoconjugate-
lectin interaction is the topology of both the glycoconjugate
and lectin. In this respect, the relative orientation and spac-
ing of the carbohydrate residues in the glycoconjugate in re-
lation to the distribution of the Carbohydrate Recognition
Domains (CRDs) on the lectins is of fundamental impor-
tance.[18,19] The hepatocyte cells on liver express lectins that
recognize terminal b-galactosyl residues on desilylated gly-
coproteins- asialoglycoprotein receptor (ASGPR).[20] The
targeting of endogenous lectins for drug delivery is an ap-
pealing concept.[21] The ASGPR can be targeted by attach-
ing galactose residues to a desired carrier containing effi-
cient reporter groups.[22–26] The pioneering work of Lee and
others has demonstrated that the order of increasing affinity
(in vivo and in vitro) of multivalent glycoconjugates for the
ASGPR is tetra> tri>di>mono.[52]
The targeting of the ASGPR has been demonstrated both
in a cell line and mice with a 111In-radiolabelled galactopyra-
nosyl conjugate of DOTA (1,4,7,10-tetrakis(carboxymethyl)-
1,4,7,10-tetraazacyclododecane).[27] 99mTc-DTPA-GSA, a
conjugate of galactosylated serum albumin (GSA) with
99mTc-DTPA (DTPA=3,6,9-tris(carboxymethyl)-3,6,9-tria-
zaundecan-1,11-dioic acid), is useful in SPECT (single
photon emission computed tomography) hepatic imaging to
assess ASGPR in mice[28] and used clinically in humans.[29,30]
Monocrystalline iron oxide nanoparticles (MION) conjugat-
ed to the bovine plasma protein asialofetuin (ASF),
(MION-ASF),[31] arabinogalactan (AG)-coated ultra-small
superparamagnetic iron oxide particles (USPIO), (AG-
USPIO),[32,33] spin-labelled arabinogalactan,[34] and a Gd-
DTPA conjugate of polylysine (PL) derivatized with galac-
tosyl groups (Gd-DTPA-gal-PL),[35] have also been devel-
oped as potential contrast agents for liver MRI by targeting
the hepatocyte ASGPR and tested in cells and mice.
In this paper we report the synthesis and characterization
of a series of multivalent lanthanide(iii)–glycoconjugates,
based on DOTA-monoamide functionalized chelators
(Figure 1). DOTA-like chelators are well known to form
LnIII chelates of high thermodynamic and kinetic stability,
which is of crucial importance for in vivo applications.[36]
The covalent binding of GdIII chelates to macro and bio-
molecules[7,8] and the formation of supramolecular assem-
blies[15] have been reported to slow down the tumbling rate
of the paramagnetic chelates which leads then to higher re-
laxivities. In the present work, the in vitro relaxivity of the
GdIII–glycoconjugates was measured and the parameters
that influence relaxivity were determined. We hypothesised
that the glycoconjugates-lectin association could substantial-
ly slow down the rotation and therefore enhance proton re-
laxivity of the GdIII-labelled glycoconjugates. This could be
the basis of a new class of paramagnetic CAs targeted to
lectins, both soluble and membrane-bound. In order to test
this concept we studied the interaction of GdIII–glycoconju-
gates in vitro with the model lectin Ricinus communis agglu-
tinin (RCA) through relaxometric measurements. To our
knowledge this is the first time that the interaction between
a GdIII–glycoconjugate and a lectin is experimentally investi-
gated in the context of MRI.
Results and Discussion
Synthesis of the ligands : We devised the synthesis of a series
of glycoconjugates of metal complexes, which includes vari-
ous galactose (Gal), glucose (Glc) and lactose (Lac) deriva-
tives of different valencies, namely the monoderivatives 1
(DOTAGal, DOTAGlc, DOTALac), the divalent glycocon-
jugates 2 (DOTAGal2, DOTAGlc2, DOTALac2) and the tet-
ravalent glycoconjugate 3 (DOTAGal4) (Figure 1).
We have devised a convergent synthesis for these ligands.
A metal chelator block and a sugar block suitably function-
alised were synthesised separately. Subsequent coupling af-
forded the fully protected glycoconjugates, which were then
deprotected to give the final compounds 1, 2 and 3.
The metal pro-chelator block 7 is a protected amino-func-
tionalized DOTA monoamide derivative (Scheme 1).
As sugar block we used a carboxylic acid-functionalised
glycodendrimer, prepared as illustrated for generation 1
(G1) dendromers 10[37] (Scheme 2).
Generation 2 (G2) dendromer 12 was prepared in a con-
vergent way from diamine 9 and TFA salt 11a (Scheme 3).
The synthesis of diamine 9 was accomplished by a modifi-
cation of RoyQs original procedure[37] (Scheme 4).
The standard DCC/HOBt (DCC=dicyclohexylcarbodi-
imide; HOBt=1-hydroxybenzotriazol) coupling procedure
revealed successful for preparing fully protected monovalent
18, divalent 17 and tetravalent 16- glycoconjugates. A two-
step deprotection, TFA/CH2Cl2 followed by KOMe/EtOH,
afforded the fully deprotected monovalent 1, divalent 2 and
tetravalent 3 glycoconjugates (Schemes 5 and 6).
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The characterization of intermediate fully protected com-
pounds, especially glycoconjugates 16, 17 and 18 by
1H NMR spectroscopy proved difficult due to extensive
broadening and overlapping of
signals. The assignment of the
1H and 13C NMR spectra from
fully deprotected compounds in
D2O revealed even more chal-
lenging, as experienced by
other groups working with dif-
ferent types of multivalent gly-
coconjugates.[19,37] High resolu-
tion mass spectrometry
(HRMS) confirmed the identity
of the final compounds.
NMR characterization of the glycoconjugate ligands in
aqueous solution : The 1H NMR spectra of the DOTAGal
(1a), DOTAGlc (1b), DOTALac (1c), DOTAGal2 (2a),
Figure 1. Structure of monovalent 1, divalent 2 and tetravalent 3 glycoconjugate ligands.
Scheme 1. a) BrCH2C(O)OEt, CH2Cl2; b) BrCH2C(O)OtBu/K2CO3, CH3CN; c) neat H2N(CH2)2NH2.
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DOTAGlc2 (2b), DOTALac2
(2c) and DOTAGal4 (3) ligands
(10mm) in D2O were obtained
in the pH 0.90–9.50 range, at
25 8C, 60 8C and 80 8C and fully
assigned using the DQF-COSY
technique. The 1H shifts at
pH 7.0 are listed in the Experi-
mental section.
In all cases, changing the pH
did not affect the sugar proton
resonances, but had a profound
effect on the DOTA macrocy-
clic and pendant arm CH2 sig-
nals. The CH2 signals from all
pendant arms except one re-
mained sharp throughout the
pH range, as well as the signals
from the macrocyclic CH2 pro-
tons, which are very broad
below pH 3, due to the rigidify-
ing effect of the presence of in-
ternal hydrogen bonds.[38] These
signals sharpen considerably
and shift to low frequencies as
the pH increases above 3.0, due
to successive selective deprotonation of some of the nitro-
gens and carboxylate oxygens, destroying most of those in-
ternal hydrogen bonds. A temperature increase has a similar
sharpening effect on those resonances.
The CH2 resonances of the bridging moieties are generally
sharp, indicating flexibility, and have almost no pH depend-
ence, with some exceptions. In DOTAX2 (X=Gal, Glc and
Lac) and in DOTAGal4, the NCH2C(O) proton signals shift
somewhat (eg. from 4.06 ppm at pH 1.1 to 4.12 ppm at
pH 5.2, for DOTAGlc2) but broaden and disappear at pH >
5.5, while some broadening is also observed for the NCH2
protons close to the branching protonated nitrogen atoms.
This indicates that an interaction occurs at high pH between
these positively charged nitrogens and the negatively charg-
ed deprotonated DOTA-monoamide pendant carboxylate
groups.
Scheme 2. a) DCC/HOBt, CH2Cl2; b) TFA/CH2Cl2 1:3.
Scheme 3. a) i) DIPEA/CH2Cl2, ii) DCC/HOBt, CH2Cl2; b) TFA/CH2Cl2 1:3.
Scheme 4. a) i) CF3C(O)OEt, CH2Cl2; ii) BrCH2C(O)OtBu/DIPEA, CH3CN; b) Dowex 1X2-100-OH
 ,
CH3OH/H2O.
Scheme 5. a) DCC/HOBt, CH2Cl2; b) i) TFA/CH2Cl2, ii) KOMe/EtOH
iii) Amberlyst 15, elution with NH3(aq).
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NMR studies of some LnIII–glycoconjugates : The 1H NMR
spectra of the paramagnetic complexes SmIII-DOTAGal,
SmIII-DOTAGlc2, Sm
III-DOTALac2 and Eu
III-DOTALac2
were obtained in D2O at 25 8C (see Figure 2 for Eu
III-DO-
TALac2). For all the Sm
III complexes and the EuIII complex,
the protons of the sugar moieties and the bridging arms are
hardly perturbed by the paramagnetic center, with very
small broadenings and paramagnetic shifts smaller than
0.05 ppm (with the exception of the NCH2CH2 protons of
the EuIII-DOTALac2 complex, with a paramagnetic shift of
+0.30 ppm). This indicates that they have preferred solution
conformations with the sugar and linker moieties extended
away from the LnIII-binding chelate moiety, due to the r6
and r3 dependency, respectively, of the dominant dipolar
contributions to the paramagnetic relaxation and shift in-
duced by the LnIII ion, where r is the LnIII-proton distance
in the complex.[39] However, the CH2 resonances within the
macrocyclic ring and pendant
arms of the derivatized DOTA
moiety are strongly shifted, and
somewhat broadened. These
features show close similarities
with the parent DOTA and re-
lated complexes.[39–42] These
complexes can adopt two dia-
stereomeric structures, the
square antiprismatic (M) and
the twisted square antiprismatic
(m) structure, which differ in
the layout of the coordinating
arms relative to the macrocyclic
ring, with a twist angle between
the two planes formed by the
four nitrogens and four oxygens
in the coordination sphere of
the LnIII of about 408 (M) and
208 (m). For the same LnIII
complex, the paramagnetically
shifted 1H resonances of the M
isomer cover a spectral window
about double of the m
isomer.[40,41] The EuIII-DOTA-
Lac2 complex shows two sets of
signals corresponding to M- and
m- type structures, with a rela-
tive intensity ratio of about 3:1
(Figure 2), similar to what has
been found for other assymetric
DOTA derivatives.[42] The para-
magnetic centers are expected
to cause a separate resonance
for each of the protons of each
isomer in the assymetrically
substituted amide ligand, with a
total of 24. All of these are
seen for the M isomer, in the
+33.5 to 16.6 ppm range, but
only some for the m isomer, for
example, at ppm 8.8, 7.2,
6.0, 1.2. A comparison of the relative shifts of the M
isomer of EuIII-DOTALac2 and Eu
III-DOTA[43] allows the as-
signment of the resonances of this isomer to the types of
protons present in the DOTA moiety of the glycoconjugate
(ppm: 16.6, 15.5, 15.0, 14.8 for ac2; 14.6, 12.5,
12.1, 11.4 for ax2; 10.6, 7.9, 7.6, 6.8 for ac1; 5.6,
4.8, 3.1, 2.9 for eq2; 1.9, 0.1, 0.0, +1.9 for eq1,
+31.1, +31.4, +32.6, +33.5 for ax1, Figure 2). In the pres-
ent case, the orientation of the substituent did not lead to a
doubling of these resonances as a consequence of the forma-
tion of two structural isomers, indicating that fast rotation
about the amide bond occurs, similar to what has been
found for other monosubstituted amide derivatives, but not
in disubstituted ones.[42]
The signals are somewhat broadened at 25 8C due to
M$m isomeric exchange,[41] but this exchange broadening
effect is much more noticeable for the SmIII complexes,
Scheme 6. a) i) DIPEA/CH2Cl2, ii) DCC/HOBt, CH2Cl2; b) i) TFA/CH2Cl2 1:3, ii) KOMe/EtOH, iii) Amberlyst
15, elution with NH3(aq).
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where only six broad resonances are detectable at +7.2,
+4.2, +1.6, +1.4, +1.2 and 2.1 ppm, which, when com-
pared with those of SmIII-DOTA,[40] can be assigned, respec-
tively, to the ac2, ax2, ac1, eq1, eq2 and ax1 protons of the M
isomer. However, this broadening causes overlap of the four
signals from each type of proton in the four chelate units,
and does not allow observation of the m isomer.
NMRD studies of the GdIII–glycoconjugates and their bind-
ing to RCA : The proton relaxivity of the GdIII complexes
describes the efficiency of the magnetic dipolar coupling be-
tween the water proton nuclei and the paramagnetic metal
ion, therefore it is a direct measure of the efficacy of the
complex as a contrast agent. The paramagnetic ion enhances
the relaxation rates of the bulk water protons by long-range
and short-range interactions (outer sphere and inner sphere
relaxation, respectively). The inner sphere term is governed
by the exchange rate of the inner sphere water molecule
(kex), the rotational correlation time of the complex (tR),
and the longitudinal and transverse electronic relaxation
rates of the GdIII (1/T1e and 1/T2e). The outer sphere contri-
bution to the overall proton relaxivity depends on the elec-
tron spin relaxation rates and the diffusion coefficient for
the diffusion of a water proton away from a GdIII complex
(see Appendix).[43]
The proton relaxivities have been measured for the GdIII
glycoconjugates of the three types of sugars at three differ-
ent temperatures (25, 37 and 60 8C) between 0.2 and
20 MHz proton Larmor frequency. They are all characteris-
tic of low molecular weight GdIII complexes. As a represen-
tative example we show the nuclear magnetic relaxation dis-
persion (NMRD) profiles of the divalent glucose derivative
GdIII-DOTAGlc2 (Figure 3). The NMRD curves of the two
divalent derivatives of galactose and lactose, GdIII-DOTA-
Gal2 and Gd
III-DOTALac2, respectively, can be found in the
supporting information. The profiles have been fitted to the
usual Solomon-Bloembergen-Morgan theory that relates the
paramagnetic relaxation rates to the microscopic parameters
of the GdIII complex (for equations see Appendix). As it has
Figure 2. 1H NMR spectrum of EuIII-DOTALac2 in D2O, pH 7.0, T=25 8C.
Figure 3. Variable temperature NMRD profiles for GdIII-DOTAGlc2. T=
25 (~); 37 (&) and 60 8C (*). The lines represent the least squares fit to
the experimental data points as described in the text.
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been pointed out previously, given the large number of fac-
tors influencing proton relaxivity, the parameters describing
relaxivity cannot be determined exclusively from the often
featureless NMRD profiles. Therefore an independent
access to some of the parameters is usually required. Water
exchange rates have been determined on numerous GdIII
chelates, including [Gd(DOTA)(H2O)]
 , [Gd(DTPA)-
(H2O)]
2 and their different amide derivatives. As a relative-
ly general rule, it was found that the replacement of each
carboxylate coordinating group of the poly(amino carboxy-
late) ligand by an amide function results in a decrease of the
water exchange rate by a factor of 3–4.[43] This decrease is
independent of the substituents on the amide group. The
glycoconjugates studied here are all monoamide derivatives
of DOTA4. Therefore, based on the large body of available
data on the water exchange on similar DOTA-monoamides,
in the analysis of the NMRD profiles we fixed the rate as
well as the activation enthalpy of the water exchange to
usual values (kex
298=1.2S106 s1 and DH=30.0 kJmol1).
Moreover, the diffusion coefficient for the diffusion of a
water proton away from a GdIII chelate (DGdH
298) as well as
its activation energy is not much dependent on the nature of
low molecular weight complexes; hence in the fitting proce-
dure these two parameters were also fixed to common
values.[44] Consequently, in the analysis of the NMRD pro-
files we fitted the rotational correlation time, tR, its activa-
tion energy, ER, and the parameters describing the electron
spin relaxation, that is, the trace of the square of the transi-
ent zero-field-splitting (ZFS) tensor, D2, and the correlation
time for the modulation of the ZFS, tv. The parameters ob-
tained for the three GdIII chelates are presented in Table 1.
The rotational correlation times calculated for the differ-
ent glycoconjugates are all reasonable for small chelates,
and as expected, increase with increasing molecular weight
from the galactose and glucose derivatives to the larger size
lactose conjugates.[43] As tR values dominate the high-field
NMRD values, the relaxivities of these complexes at
20 MHz and 25 8C are significantly higher than those previ-
ously found for smaller DOTA-monoamide com-
plexes.[42,43,45] The parameters obtained for the electron spin
relaxation of the GdIII complexes are also within the usual
range for similar GdIII-DOTA monoamide chelates, with a
significant increase of D2 relative to the more symmetric
GdIII-DOTA chelate, affecting the low-field NMRD
values.[42,43,45, 46] Although in the last few years it has become
evident that the simplified model of electron spin relaxation
used here is not fully adequate to describe GdIII chelates,[47]
the application of the novel theories requires EPR data in a
large field range which was beyond the scope of the present
study.
The proton relaxivities of these small molecular weight
chelates are limited by fast rotation. This is clearly shown by
the temperature dependence of the profiles: proton relaxivi-
ties increase when the temperature decreases, thus the rota-
tion slows down.
These glycoconjugates are capable of binding to lectins. In
a solid phase competitive assay (ELLA, enzyme-linked
lectin assay) we were able to verify a mini glycoside cluster
effect in the binding of these glycoconjugates to PNA
(peanut agglutinin).[18,48]
The binding could considerably decrease the tumbling
rate of the GdIII–glycoconjugates and thus enhance their
proton relaxivity. We have performed proton relaxivity
measurements in solutions of the GdIII–glycoconjugates in
the presence of Ricinus communis agglutinin, RCA120 (MW=
120000) as model lectin. RCA120 is a S–S dimer of two sub-
units. Each subunit (MW=60000) is a heterodimeric protein
made of two S–S linked chains, A and B chains. The B chain
is made of two globular domains, with a carbohydrate bind-
ing site, specific for terminal b-linked galactosides, per
domain. The A chain has N-glycosidase activity which inhib-
its protein synthesis. The two subunits are associated cova-
lently by a SS bond between the two A chains. The dimer
is further stabilised by contacts on the interface.[16,17]
Under the best available experimental conditions, the
concentration of the RCA120 was 0.5%, corresponding to a
0.04 mm concentration (more concentrated solutions are not
commercially available), whereas the concentration of the
GdIII chelate was 1.0mm (at lower concentrations of the par-
amagnetic species the relaxivity measurements become im-
precise). Assuming an association constant of 104[16] and two
independent binding sites on the RCA molecule, and that
the spacing of the sugar terminals on the divalent glycocon-
jugates does not allow the simultaneous clustering of both
sugars on the same molecule of RCA, in the best case sce-
nario we would have two Gd-glycoconjugate units per RCA
molecule, that is, maximum 8% of all the GdIII chelate
would be bound to the protein. For all our systems we ob-
served a slight increase (around 5%) in proton relaxivity in
a solution of 0.5% RCA120. This relaxivity increase is not
much higher than the error margin of the measurements,
therefore we prefer not to interpret this result unambigously
in terms of lectin binding. Although the bound species very
likely has a higher proton relaxivity due to slower rotation,
its concentration is too low and therefore a substantial in-
crease in relaxivity is difficult to observe. A clear effect of
the glycoconjugate-lectin association on the in vitro proton
relaxivity could only be observed with considerably higher
concentrations of the lectin-bound GdIII complex. The only
possibility to increase the percentage of bound Gd-species,
and therefore the relaxivity, is to have a higher concentra-
tion of lectin in the assay, however the lectin availability is a
limiting factor.
Table 1. Parameters obtained from the analysis of the NMRD profiles
for the GdIII–glycoconjugates.[a]
DOTAGal2 (2a) DOTAGlc2 (2b) DOTALac2 (2c)
k298ex /10
6 s1 1.2 1.2 1.2
DH/kJ mol1 30.0 30.0 30.0
t 298rH /ps 2426 2618 30610
ERH/kJmol
1 28.30.3 27.20.2 29.90.2
t298v /ps 352 393 335
Ev/kJ mol
1 1 1 1
D2/1020 s2 0.100.02 0.100.01 0.120.02
D 298GdH/10
10 m2 s1 24.0 24.0 24.0
EDGdH/kJmol
1 20 20 20
[a] Parameters in italic have been fixed in the fit.
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The feasibility of in vivo MRI applications based on re-
ceptor binding in general depends on the concentration of
the given receptor as well as on the relaxivity of the recep-
tor-bound species. Targeted receptors in cells in general are
usually present at concentrations within the range 109–
1013 molg1 of tissue.[49] The minimal concentration of a
contrast agent that is detectable by MRI (the concentration
necessary to observe a signal enhancement) has been esti-
mated between 5S107 molg1 for the low molecular weight
Gd(HP-DO3A)(H2O) (r1=3.7mm
1 s1) and 1.9S
1010 molg1 for a 6th generation, Gd(DTPA)-loaded den-
drimer (r1=5800mm
1 s1 per dendrimer) or 1.6S
1011 molg1 for superparamagnetic iron oxide particles
(r2=72000mm
1 s1 per particle) (HP-DO3A=1,4,7-tris(car-
boxymethyl)-10-hydroxypropyl-1,4,7,10-tetraazacyclo-dodec-
ane).[50] In addition to receptor binding on the cell surface,
receptor mediated endocytosis can lead to accumulation of
the magnetic species inside the cell. With an efficient inter-
nalization mechanism, the concentration of the MRI con-
trast agent inside the cell can largely exceed what is expect-
ed solely by surface binding, thus it can help circumvent the
problem of low MRI sensibility. Preliminary results of bio-
distribution studies with Wistar rats using 153Sm-labeled gly-
coconjugates of different valencies and sugar type indicate a
specific hepatic uptake of the galactose and (to a less
extent) lactose glycoconjugates through the ASGPR (results
to be published separately). However, the feasibility of MR
imaging based on the specific hepatic uptake of the GdIII
glycoconjugates remains to be tested.
Conclusions
Conjugating a small glycodendrimer ending with galactose
unit(s) to a DOTA scaffold via an amide bond generates a
new class of stable hydrophilic glycoconjugates. The glyco-
dendrimer architecture was found suitable to vary the sugar
type and valence in an interactive way from a reduced
number of building blocks.
The LnIII chelates of these glycoconjugates have predomi-
nant square antiprismatic solution structures of the coordi-
nating DOTA moiety, with one inner-sphere water molecule.
The flexibility of the glycodendrimer moiety in solution
somehow limits the relaxivity of their GdIII complexes to
values lower than expected from their molecular weight.
However we envisaged that the lectin–glycoconjugate inter-
action could considerably slow down the tumbling rate and
therefore increase the relaxivity of the GdIII chelates. Fur-
ther studies are needed in order to unambiguously verify
this effect. Our results open the way for the study of GdIII–
glycoconjugates as potential candidates for lectin-mediated
molecular imaging agents.
Experimental Section
Materials and analysis : Chemicals were purchased from Sigma-Aldrich
and used without further purification. Solvents used were of reagent
grade and purified by usual methods. Reactions were monitored by TLC
on Kieselgel 60 F254 (Merck) on aluminium support. Detection was by ex-
amination under UV light (254 nm), by adsorption of iodine vapour and
by charring with 10% sulphuric acid in ethanol. Flash chromatography
was performed on Kieselgel 60 (Merck, 230–400 mesh). The relevant
fractions from flash chromatography were pooled and concentrated
under reduced pressure, T<40 8C. FAB mass spectra (positive mode)
were recorded using a VG Autospec mass spectrometer with 3-nitroben-
zyl alcohol (NBA) as matrix.
NMR spectra : 1H NMR (1D and 2D) and 13C NMR spectra were run on
a Varian Unity Plus 300 NMR spectrometer, operating at 299.938 and
75.428 MHz, for 1H and 13C, respectively. Chemical shifts (d) are given in
ppm relative to the CDCl3 solvent (
1H, d 7.27; 13C 77.36) as internal stan-
dard. For 1H and 13C NMR spectra recorded in D2O, chemical shifts (d)
are given in ppm, respectively, relative to TSP as internal reference (1H,
d 0.0) and tert-butanol as external reference (13C, CH3 d 30.29).
13C NMR
spectra were proton broad-band decoupled using a decoupling scheme.
The pD of the D2O solutions was adjusted with DCl or CO2-free NaOD
and converted to pH values using the isotopic correction pH pD-0.4. The
pD values were measured on a HANNA pH meter with a HI1310 com-
bined electrode (HANNA instruments, Italy).
NMRD measurements : The 1/T1 nuclear magnetic relaxation dispersion
(NMRD) profiles of the water protons were obtained on a Spinmaster
FFC fast cycling NMR relaxometer (Stelar), covering a continuum of
magnetic fields from 5S104 to 0.47 T (corresponding to a proton
Larmor frequency range of 0.022–20 MHz). The concentration of the
GdIII solutions was determined by ICP (Perkin–Elmer Instruments,
Optim 200 DV).
Synthesis of monoalkylated cyclen (5): A solution of ethylbromoacetate
(3.0 g; 18.0 mmol) in CH2Cl2 (30 mL) was added dropwise over 30 min to
an ice-cooled solution of cyclen (4.08 g, 23.7 mmol) in CH2Cl2 (50 mL).
After 2 h the reaction mixture was allowed to reach room temperature
and further stirred for 24 h. The white precipitate was filtered of and the
solvent was removed under reduced pressure to give a yellow oil. Purifi-
cation by flash chromatography (100% CH2Cl2 ! CH2Cl2/MeOH/NH3/
H2O 70:30:5:5) afforded the title compound (4.83 g, 79%) as a white
syrup. 1H NMR (300 MHz, CDCl3): d=1.27 (t, J=7.2 Hz, 3H; CH3), 2.84
(m, 8H), 2.95 (m, 8H), 3.49 (m, 2H), 4.16 (q, J=7.2 Hz, 3H;
C(O)OCH2).
Synthesis of orthogonally alkylated cyclen (6): K2CO3 (9.43 g, 68.3 mmol)
was added to a solution of monoalkylated cyclen 5 (2.94 g, 11.4 mmol) in
MeCN (100 mL). To this suspension a solution of tert-butylbromoacetate
(6.66 g, 34.1 mmol) in MeCN (30 mL) was added dropwise over 20 mi-
nutes. The suspension was vigorously stirred at room temperature for 4 h.
The suspended solid was removed by filtration, the solvent was evaporat-
ed under reduced pressure, and the residue was purified by dry flash
chromatography (100% CH2Cl2!20% MeOH/CH2Cl2) to give the title
compound (5.72 g, 84%) as a white foam. 1H NMR (300 MHz, CDCl3):
d=1.15 (t, J=7.2 Hz, 3H; C(O)OCH2CH3), 1.33, 1.34 and 1.35 (s, 27H;
tBu), 1.80–3.70 (we observed a set of very broad multiplets with an inte-
gration corresponding to 24H), 4.04 (q, J=7.2 Hz, 3H; C(O)OCH2); MS
(FAB+ , NBA): m/z (%): 639 (89) [M+K]+ , 623 (100) [M+Na]+ ; HRMS
(FAB+ , NBA): m/z : calcd for C30H56N4NaO8 623.3996, found: 623.3981
[M+Na]+ .
Synthesis of ethylenediamine-functionalised cyclen (7): Compound 6
(5.24 g, 8.72 mmol) was dissolved in neat ethylenediamine (3 mL; 2.70 g,
44.9 mol) and the resulting solution was stirred at room temperature for
72 h. Ethylenediamine was removed under reduced pressure and the resi-
due was dried under vacuum to give a light yellow foam. This was puri-
fied by dry flash chromatography with (100% CH2Cl2!CH2Cl2/MeOH
1:1) to give the title compound (4.18 g, 68%) as a white foam. 1H NMR
(300 MHz, CDCl3): d=1.46 (s, 27H; tBu), 1.80–3.84 (we observed a set
of very broad signals with an integration corresponding to 30H), 8.18
(broad, 1H; C(O)NH); 13C NMR (75.6 MHz, CDCl3): d=27.68 and 27.84
(Me), 36.60 (CH2), 40.03 (CH2), 55.39 (CH2), 55.51 (CH2), 55.90 (CH2),
81.61 and 81.70 (CMe3), 172.17 (C(O)), 172.27 (C(O)); MS (FAB
+ ,
NBA): m/z (%): 637 (100) [M+Na]+ ; HRMS (FAB+ , NBA): m/z : calcd
for C30H58N6NaO7 637.4265, found 637.4246 [M+Na]
+ .
Synthesis of orthogonally protected amine (15): A solution of ethyltri-
fluoroacetate (2.24 g, 15.6 mmol) in dichloromethane (20 mL) was added
dropwise over 1 h to an ice-cooled solution of 3,3-iminobis(propylamine)
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(14) (0.94 g, 7.1 mmol) in dichloromethane (20 mL). The reaction mixture
was allowed to reach room temperature and further stirred for 16 h. The
solvent was removed under reduced pressure to give a colourless oil.
TLC analysis (CH2Cl2/MeOH 4:1) revealed a major spot and a small spot
ninhydrin-positive). The product was used on the next reaction without
further purification. The oil was redissolved in MeCN (50 mL) and diiso-
propylethylamine (DIPEA) (0.92 g, 7.1 mmol) was added. tert-Butylbro-
moacetate (1.38 g, 7.1 mmol) was added dropwise over 5 min and the re-
action mixture was stirred at room temperature for 6 h with formation of
a white precipitate. The reaction mixture was filtered to remove the
white precipitate (bromide salt of DIPEA) and the solvent was removed
under reduced pressure to give a light red oil. The product was purified
by flash chromatography with (100% CH2Cl2!10% MeOH/CH2Cl2) to
give the title compound as a colourless oil (2.50 g, 81% yield over two
steps). 1H NMR (300 MHz, CDCl3): d=1.40 (s, 9H; tBu), 1.67 (qt, J=
6.3 Hz, 4H; NCH2CH2), 2.50 (t, J=6.3 Hz, 4H; NCH2), 3.12 (s, 2H;
NCH2C(O)), 5.39 (appq, J=6.3 Hz, 4H; NCH2CH2CH2), 8.40 (br t), 2H;
NHC(O)CF3);
13C NMR (75.6 MHz, CDCl3): d=25.43 (NCH2CH2), 27.75
(CH3), 38.07 (NCH2CH2CH2), 51.83 (NCH2), 55.76 (NCH2C(O)), 81.98
(OC(CH3)3), 115.89 (q, J=287 Hz, CF3), 157.34 (q, J=37.0 Hz,
NHC(O)CF3), 171.18 (C(O)OtBu).
Synthesis of bis-amine (9): Dowex1-X2-100 resin (30 mL, wet resin,
OH) was added to a solution of compound 15 (3.10 g, 7.1 mmol) in
MeOH/H2O (50/20 mL). The reaction mixture was shaken at room tem-
perature for 72 h. The resin was filtered off, washed with water and meth-
anol, and the filtrate was concentrated under reduced pressure to give a
yellow oil. The compound was purified by flash chromatography (100%
CH2Cl2! CH2Cl2/MeOH/H2O/NH3 40:60:10:10) to give the title com-
pound as a colourless thick oil (1.21 g, 69%). 1H NMR (300 MHz,
CDCl3): d=1.36 (s, 9H; tBu), 1.51 (qt, J=6.9 Hz, 4H; NCH2CH2), 2.50
(t, J=6.9 Hz, 4H; NCH2), 2.65 (t, J=6.9 Hz, 4H; NCH2CH2CH2), 3.09
(s, 2H; NCH2C(O));
13C NMR (75.6 MHz, CDCl3): d=27.93 (CH3),
30.64 (NCH2CH2), 40.15 (NCH2CH2CH2), 51.77 (NCH2), 55.85
(CH2C(O)), 80.60 (C(CH3)3), 170.71 (C(O)).
Synthesis of divalent peracetylated thioglycosides 10a–c : Typical proce-
dure illustrated for 10a : To a solution of bis-amine 9 (0.95 g, 3.87 mmol)
in ice-cooled dichoromethane (100 mL) was sequentially added peracety-
lated (galactosylthio)propionic acid 8a (3.55 g, 8.13 mmol), HOBt (1.23 g,
9.76 mmol) and DCC (1.67 g, 9.76 mmol) were added dropwise as a so-
lution in dicloromethane (10 mL). After 15 minutes the reaction mixture
was removed from the ice bath and allowed to reach room temperature.
The reaction mixture was further stirred at room temperature overnight.
The precipitate dicyclohexylurea (DCU) was removed by filtration and
washed with dichloromethane. The filtrate was concentrated under re-
duced pressure to give thick syrup. The compound was taken into ethyl
acetate (200 mL) and sequentially washed with NaHCO3 (sat. sol. ; 3S
100 mL) and brine (100 mL). The organic phase was concentrated under
reduced pressure to give a white foam. Purification by dry flash chroma-
tography (100% CH2Cl2!MeOH/CH2Cl2 1:1) afforded the title com-
pound as a white foam (4.02 g, 96%). 1H NMR (300 MHz, CDCl3): d=
1.47 (s, 9H; tBu), 1.64 (m, 4H; NCH2CH2), 1.99, 2.05, 2.06, 2.16 (s, 4S
6H, OAc), 2.51 (m, 8H; overlapping signals from NCH2 and SCH2CH2),
2.91–2.06 (m, 4H; SCH2), 3.14 (s, 2H; NCH2C(O)), 3.35 (appq, J=
5.4 Hz, 4H; NCH2CH2CH2), 3.95 (appt, J=6.3 Hz, 2H; H-6a), 4.14 (m,
4H; H-6b, H-5), 4.57 (d, J=9.9 Hz, 2H; H-1), 5.05 (dd, J=9.9, 3.3 Hz,
2H; H-3), 5.21 (app t, J=9.9 Hz, 2H; H-2), 5.44 (d, J=3.3 Hz, 2H; H-4),
7.02 (brm, 2H; C(O)NH); MS (FAB+ , NBA): m/z (%): 1082 (100) [M]+ ;
HRMS (FAB+ , NBA): m/z : calcd for C46H72N3O22S2 1082.4049, found
1082.4038 [M+H]+ .
Compound 10b : Starting from deprotected bis-amine 9 (0.516 g,
2.10 mmol) and peracetylated (glucosylthio)propionic acid 8b (2.02 g,
4.62 mmol), 10b was obtained as a white foam (2.27 g, 96%). 1H NMR
(300 MHz, CDCl3): d=1.46 (s, 9H; tBu), 1.62 (m, 4H; NCH2CH2), 2.00,
2.03, 2.04, 2.09 (s, 4S6H, OAc), 2.51 (m, 8H; overlapping signals from
NCH2 and SCH2CH2), 2.81–3.03 (m, 4H; SCH2), 3.14 (s, 2H;
NCH2C(O)), 3.33 (m, 4H; NCH2CH2CH2), 3.71 (m, 2H; H-5), 4.10–4.34
(m, 4H), 4.58 (d, J=10.2 Hz, 2H; H-1), 5.0 (t, J=10.2, 2H; H-2), 5.07 (t,
J=10.2, 2H; H-4), 5.22 (t, J=9.3, 2H; H-3), 7.06 (brm, 2H; NHC(O));
MS (FAB+ , NBA): m/z (%): 1083 (100) [M+H]+ ; HRMS (FAB+ , NBA):
m/z : calcd for C46H72N3O22S2 1082.4049, found 1082.4059 [M+H]
+ .
Compound 10c : Starting from deprotected bis-amine 9 (1.05 g,
4.28 mmol) and peracetylated (lactosylthio)propionic acid 8c (6.52 g,
9.00 mmol), 10c was obtained as a white foam (7.10 g, 97%). 1H NMR
(300 MHz, CDCl3): d=1.47 (s, 9H; tBu), 1.68 (m, 4H; NCH2CH2), 1.96,
2.03, 2.04, 2.05, 2.06, 2.13, 2.15 (s, 7S6H, OAc), 2.47 (m, 4H; SCH2CH2),
2.56–2.76 (brm, 4H; NCH2), 2.78–3.06 (m, 4H; SCH2), 3.35 (m, 6H),
3.62 (m, 2H; H-5), 3.87 (m, 2H), 3.90 (m, 2H), 4.10 (m, 6H), 4.54 (d, J=
10.2, 2H; H-1’), 4.61 (d, J=10.8 Hz, 2H; H-1), 4.91 (t, J=9.6, 2H; H-2),
4.97 (dd, J=10.2, 3.3 Hz, 2H; H-3’), 5.11 (dd, J=10.6, 7.5 Hz, 2H; H-2’),
5.19 (t, J=9.3 Hz, 2H; H-3), 5.35 (d, J=3.3 Hz, 2H; H-4’), 7.02 (br t,
2H; NHC(O); MS (FAB+ , NBA): m/z (%): 1659 (48.6) [M]+ ; HRMS
(FAB+ , NBA): m/z : calcd for C70H104N3O38S2 1658.5739, found 1658.5671
[M+H]+ .
Synthesis of tetravalent peracetylated thiogalactoside 12 : A solution of
divalent thiogalactoside 10a (2.83 g, 1.25 mmol) was stirred overnight
with CH2Cl2/TFA (3:1, 20 mL). The solvent was removed under reduced
pressure to give a light yellow foam, which was redissolved in CH2Cl2
(20 mL) and the solvent was removed under reduced pressure. This pro-
cedure was repeated several times and the compound was further dried
under vacuum to give 11a as a thick light yellow foam. 1H NMR analysis
revealed the disappearance of the signal at d=1.47 assigned to the tert-
butyl group. No further purification or characterisation was carried out
(we assumed a 100% yield on the deprotection reaction). The product
was dissolved in ice-cooled CH2Cl2 (10 mL) and titrated (pH paper) to
pH 9–10 with DIPEA. To this solution was added a solution of deprotect-
ed bis-amine 9 (0.146 g, 0.595 mmol) in CH2Cl2 (10 mL), followed by
HOBt (0.220 g, 1.49 mmol) and a solution of DCC (0.300 g, 1.49 mmol)
in CH2Cl2 (10 mL) was added dropwise. The resulting mixture was stirred
for 15 minutes while cooled on an ice bath, allowed to reach room tem-
perature and further stirred for 24 h. The precipitated DCU was removed
by filtration and the solvent was removed under reduced pressure. The
resulting oil was redissolved in ethyl acetate (200 mL) and washed with
NaHCO3 (sat. sol.; 3S50 mL) and brine (50 mL). The solvent was re-
moved under reduced pressure, and the residue was purified by dry flash
chromatography (100% CH2Cl2!20% EtOH/CH2Cl2) to give the title
compound as a white foam (1.12 g, 83%). 1H NMR (300 MHz, CDCl3),
selected signals: d=1.46 (s, 9H; tBu), 1.64 (m, 8H; NCH2CH2), 1.98,
2.05, 2.06, 2.16 (s, 4S12H; OAc), 2.55 (m, 20H), 2.86–3.10 (m, 16H),
3.32 (m, 14H), 3.98 (app t, J=6.6 Hz, 4H; H-6a), 4.14 (m, 8H; H-6b, H-
5), 4.59 (d, J=9.9 Hz, 4H; H-1), 5.06 (dd, J=10.0, 3.4 Hz, 4H; H-3), 5.20
(app t, J=9.9 Hz, 4H; H-2), 5.44 (d, J=2.4 Hz, 4H; H-4), 7.02 (br, 4H;
C(O)NH); HRMS (ESI): m/z : calcd for C96H151N9O44S4 1130.9363, found
1130.9385 [M+2H]2+ .
Synthesis of fully protected monovalent glycoconjugates 18a–c : Typical
procedure illustrated for 18a : A round-bottomed flask was charged with
ethylenediamine-functionalised cyclen 7 (0.375 g, 0.61 mmol), peracety-
lated galactosylthiopropionic acid 8a (0.292 g, 0.67 mmol) and HOBt
(0.100 g, 0.67 mmol) in CH2Cl2 (20 mL). The reaction was initiated by
adding dropwise a solution of DCC (0.140 g, 0.67 mmol) in CH2Cl2
(5 mL). The reaction mixture was stirred while cooled on an ice bath for
15 minutes, allowed to reach room temperature and further stirred for
16 h. The precipitate DCU was filtered off, the filtrate was concentrated
under reduced pressure and the resulting yellow foam was redissolved in
EtOAc (100 mL). The organic phase was washed sequentially with
KHCO3 (sat. sol. 3S50 mL) and brine (50 mL) and concentrated under
reduced pressure to give a white foam. The product was purified by dry
flash chromatography (100% CH2Cl2!30% MeOH/CH2Cl2) to give the
title compound as a white foam (0.580 g, 92%). 1H NMR (300 MHz,
CDCl3) for compounds 18a–c the signals from the cyclen moiety and
from the ethylenediamine linker, N(CH2)2)N, NCH2C(O) and
C(O)NH(CH2)2)NHC(O)), respectively, appear in the range of d=2.40–
3.60 as a set of broad multiplets overlaped with signals from the sugar
moiety. Selected signals: 1H NMR (300 MHz, CDCl3): d=1.44 (s, 3S9H;
tBu), 1.96, 2.01, 2.04, 2.13 (s, 4S3H; OAc), 4.15 (m, 3H; H-5, H-6a,
H-6b), 4.90 (d, J=9.3 Hz, 1H; H-1), 5.11 (dd, J=9.9, 3.3, 1H; H-3), 5.18
(t, J=9.9, 1H; H-2), 5.43 (d, J=3.3 Hz, 1H; H-4), 8.35, 8.43 (C(O)NH);
MS (FAB+ , NBA): m/z (%): 1056 (100) [M+Na]+ ; HRMS (FAB+ ,
NBA): m/z : calcd for C47H80N6O17NaS 1055.5198, found 1055.5204
[M+Na]+ .
Compound 18b : Starting from 7 (0.328 g, 0.534 mmol) and 8b (0.280 g,
0.640 mmol), the title compound was obtained as a white foam (0.381 g,
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69%). 1H NMR (300 MHz, CDCl3) selected signals: d=1.46 (s, 3S9H;
tBu), 1.98, 2.00, 2.05, 2.08 (s, 4S3H; OAc), 4.04–4.38 (m, 2H), 4.54 (d,
J=10.2 Hz, 1H; H-1), 5.0 (t, J=10.2, 2H; H-2), 5.07 (t, J=10.2, 2H; H-
4), 5.22 (t, J=9.3, 2H; H-3), 8.7, 8.9 (brm, 2H; NHC(O)); MS (FAB+ ,
NBA): m/z (%): 1082 (100) [M]+ ; HRMS (FAB+ , NBA): m/z : calcd for
C46H72N3O22S2 1082.4049, found 1082.4038 [M+H]
+ .
Compound 18c : Starting from 7 (0.186 g, 0.302 mmol) and 8c (0.240 g,
0.332 mmol), the title compound was obtained was a white foam (0.358 g,
90%). 1H NMR (300 MHz, CDCl3) selected signald: d=1.45 (s, 3S9H;
tBu), 1.96, 2.02, 2.05, 2.06, 2.13, 2.15 (s, 21H; OAc), 4.73 (d, J=9.9 Hz,
1H; H-1), 5.35 (d, J=3.0 Hz, 1H; H-4’), 8.80, 9.02 (br, 2H; NHC(O));
MS (FAB+, NBA): m/z (%): 1344 (68) [M+Na]+ , 1343 (100)
[MH+Na]+; HRMS (FAB+ , NBA): calcd for C59H96N6O25NaS
1343.6044, found 1343.6074 [M+Na]+ .
Synthesis of fully protected divalent 17a–c and tetravalent 16 glycoconju-
gates : Typical procedure illustrated for 17a : A solution of divalent thio-
galactoside 10a (0.480 g, 0.44 mmol) was stirred overnight with CH2Cl2/
TFA (3:1, 12 mL). The solvent was removed under reduced pressure to
give a light yellow foam, which was redissolved in CH2Cl2 (10 mL); sub-
sequently the solvent was removed under reduced pressure. This proce-
dure was repeated several times and further dried under vacuum.
1H NMR analysis revealed the disappearance of the signal at d=1.47 as-
signed to the tert-butyl group. The compound was carried forward with-
out further purification or characterisation (we assumed a 100% yield on
the deprotection reaction). The foam was dissolved in ice-cooled CH2Cl2
(5 mL) and titrated (pH paper) to pH 9–10 with DIPEA. To this reaction
mixture was added a solution of ethylenediamine-functionalised cyclen 7
(0.246 g, 0.40 mmol) in CH2Cl2 (5 mL), HOBt (0.060 g, 0.53 mmol); sub-
sequently a solution of DCC (0.100 g, 0.53 mmol) in CH2Cl2 (5 mL) was
added dropwise. The resulting mixture was stirred for 15 min on an ice
bath, allowed to reach room temperature and further stirred overnight.
The precipitated DCU was filtered of and the solvent was removed
under reduced pressure. The resulting oil was redissolved in ethyl acetate
(50 mL) and washed with satd KHCO3 (3S50 mL) and brine (50 mL).
The solvent was removed under reduced pressure, and the residue was
purified by dry flash chromatography (100% CH2Cl2!10% EtOH/
CH2Cl2) to give the title compound as a white foam (0.593 g, 90%).
1H NMR (300 MHz, CDCl3) for compounds 17a–c and 16 : the signals
from the cyclen moiety and from the ethylenediamine linker, N(CH2)2)N,
NCH2C(O) and C(O)NH(CH2)2)NHC(O), respectively, appear in the
range of d=1.40–3.70 as a set of broad multiplets overlapped with signals
from the sugar moiety and from the dendrimer scaffold; selected signals:
1.44, 1.46 (s, 3S9H; tBu), 1.62–1.64 (m, 4H; NCH2CH2), 1.96, 2.04, 2.06,
2.14 (s, 4S6H; OAc), 2.46–2.73 (m, 8H; overlapping signals from NCH2
and SCH2CH2), 2.89–3.08 (m, 4H; SCH2), 3.28 (m, 6H), 3.95 (app t, J=
6.3 Hz, 2H; H6a), 4.14 (m, 4H; H-6b, H-5), 4.57 (d, J=9.9 Hz, 2H; H-1),
5.05 (dd, J=9.9, 3.3 Hz, 2H; H-3), 5.21 (app t, J=9.9 Hz, 2H; H-2), 5.44
(d, J=3.3 Hz, 2H; H-4), 7.02 (br, 2H; C(O)NH); MS (FAB+ , NBA): m/
z (%): 1082 (100) [M]+ ; HRMS (FAB+ , NBA): m/z: calcd for
C46H72N3O22S2 1082.4049, found 1082.4038 [M+H]
+ .
Compound 17b : Starting from compound 7 (0.522 g, 0.85 mmol) and
compound 10b (1.10 g, 1.02 mmol) the title compound was obtained
(0.874 g, 63%) as a white foam. 1H NMR (300 MHz, CDCl3) selected sig-
nals: d=1.45, 1.47 (s, 3S9H; tBu), 1.68 (m, 4H; NCH2CH2), 1.99, 2.02,
2.05, 2.09 (s, 4S6H, OAc), 2.53 (m, 4H; NCH2), 2.61 (m, 4H;
SCH2CH2), 2.84–3.05 (m, 4H; SCH2), 3.09 (br s, 2H; NCH2C(O)), 3.27
(m, 4H; NCH2CH2CH2), 3.33 (m, 4H; NCH2CH2NH), 3.82 (ddd, J=
10.0, 4.3, 2.2 Hz, 2H; H-5), 4.16 (dd, J=12.3, 2.0 Hz, 2H; H-6a), 4.27
(dd, J=12.3, 4.5 Hz, 2H; H-6b), 4.69 (d, J=10.2 Hz, 2H; H-1), 4.98 (t,
J=10.2, 2H; H-2), 5.08 (t, J=9.9 Hz, 2H; H-4), 5.22 (t, J=9.3 Hz, 2H;
H-3), 7.88 (brm, 2H; NHC(O)), 8.32 (brm, 1H; NHC(O)), 8.82 (brm,
1H; NHC(O)); MS (FAB+ , NBA): m/z (%): 1645 (100) [M]+ ; HRMS
(FAB+ , NBA): m/z : calcd for C72H119N9O28NaS2 1644.7504, found
1644.7455 [M+H+Na]+ .
Compound 17c : Starting from compound 7 (0.31 g, 0.50 mmol) and com-
pound 10c (0.912 g, 0.55 mmol) the title compound was obtained (1.01 g,
91%) as a white foam. 1H NMR (300 MHz, CDCl3) selected signals: d=
1.45, 1.47 (s, 3S9H; tBu), 1.74 (brm, 4H; NCH2CH2), 1.97, 2.03, 2.04,
2.06, 2.07, 2.13, 2.15 (s, 7S6H; OAc), 2.54 (m, 4H; SCH2CH2), 2.82–3.02
(brm, 4H; NCH2), 3.08 (s, 2H), 3.25–3.33 (m, 4H), 3.40–3.56 (m, 2H),
3.67 (m, 2H; H-5), 3.81 (t, J=9.4 Hz, 2H), 3.89 (t, J=6.6 Hz, 2H), 4.11
(m, 8H), 4.53 (d, J=9.9 Hz, 2H; H-1’), 4.59 (d, J=9.9 Hz, 2H; H-1), 4.92
(t, J=9.9 Hz, 2H; H-2), 4.95 (m, 2H; H-3’), 5.07 (dd, J=7.8, 2.7 Hz, 2H;
H-2’), 5.20 (t, J=9.3 Hz, 2H; H-3), 5.35 (d, J=3.0 Hz, 2H; H-4’), 7.79
(brm, 2H; NHC(O)), 8.30 (brm, 1H; NHC(O)), 8.83 (brm, 1H;
NHC(O)); HRMS (ESI): m/z : calcd for C96H153N9O44S2 1099.9721, found
1099.9760 [M+H+Na]+ .
Fully protected tetravalent glycoconjugate 16 : Starting from compound 7
(0.126 g, 0.20 mmol) and compound 12 (0.452 g, 0.20 mmol) the title com-
pound was obtained as a white foam (0.402 g, 72%). 1H NMR (300 MHz,
CDCl3) selected signals: 1.46 (s, 3S9H; tBu), 1.62–1.64 (m, 8H;
NCH2CH2), 1.97, 2.04, 2.06, 2.15 (s, 4S12H; OAc), 2.31 (brm, 4H), 2.57
(brm, 8H), 2.98 (brm, 8H), 3.39 (br s, 14H), 3.47 (s, 6H), 4.02 (m, 4H;
H-6a), 4.14 (m, 8H; H-6b, H-5), 4.56 (d, J=9.9 Hz, 4H; H-1), 5.06 (dd,
J=10.0, 3.4 Hz, 4H; H-3), 5.19 (app t, J=9.9 Hz, 4H; H-2), 5.43 (d, J=
2.7 Hz, 4H; H-4), 7.62, 8.44 (2brm, NHC(O)); HRMS (ESI): m/z : calcd
for C122H199N15O50S4 1401.1181, found 1401.1210 [M+2H]
2+ .
Synthesis of fully deprotected monovalent (DOTAGal (1a), DOTAGlc
(1b) and DOTALac (1c)), divalent (DOTAGal2 (2a), DOTAGlc2 (2b),
DOTALac2 (2c)) and tetravalent (DOTAGal4 (3)) glycoconjugates : Typi-
cal procedure illustrated for DOTAGal2 (2a): A solution of fully protect-
ed glycoconjugate 17a (0.500 g, 0.304 mmol) in CH2Cl2/TFA (3:1, 4 mL)
was stirred at room temperature for 24 h. The solvent was removed at re-
duced pressure, the residue was redissolved in CH2Cl2 (20 mL) and the
solvent was evaporated at reduced pressure. This procedure was repeated
several times to afford a light yellow foam that was further dried under
vacuum. 1H NMR analysis (300 MHz, CDCl3) revealed complete depro-
tection of the tert-butyl groups. No further purification was deemed nec-
essary. The foam was dissolved in ethanol (10 mL) and adjusted to pH 9–
10 with a 1m KOMe solution in ethanol. The resulting solution was stir-
red at room temperature for 16 h. The solution was adjusted to pH ~1
(pH paper) with Amberlyte 15 resin. The resin was transferred into a
column, washed with water and eluted with aq. NH3 (0.5m) solution. The
relevant fractions were pooled and the solvent was evaporated at reduced
pressure to give the title compound as a vitreous solid (0.29 g, 85%) over
two steps. 1H NMR(300 MHz, D2O, pH 7.0): d=4.50 (d, J=9.0 Hz, 2H;
H-1), 3.55 (app t, 2H; H-2), 3.66 (app t, 2H; H-3), 3.74 (dd, J=9.4,
3.3 Hz, 2H; H-4), 3.98 (app t, J=3.3 Hz, 2H; H-5), 3.75 (m, 4H; H-6a,
H-6b), 3.30 (m, 4H; C(O)NHCH2), 3.40 (m, 8H; NCH2, NCH2CH2CH2),
1.87 (brm, 4H; NCH2CH2), 2.63 (m, J=6.6 Hz, 4H; SCH2CH2), 3.01 (t,
J=6.6 Hz, 4H; SCH2), 3.82 (m, 2H; DOTA amide NCH2C(O)), 3.44 (s,
6H; DOTA acetate NCH2CO2
), 3.51, 3.20, 3.12, 2.80, 2.36, 2.23 (br, 8S
2H; DOTA macrocycle NCH2);
13C NMR (75.6 MHz, D2O): d=23.76,
26.69, 36.15, 36.30, 38.91, 39.42, 48.47 (cluster of signals), 53.27 (cluster of
signals), 54.45, 56.41, 56.76, 58.85, 61.38, 68.90, 69.65, 74.04, 79.01, 86.22
(C-1), 165.85, 169.78, 174.88, 180.14; MS (FAB+ , NBA): m/z (%): 1156
(5) [M+H+K]+ , 1119 (1) [M+H]+ ; HRMS (FAB+ , NBA): m/z : calcd for
C44H80N9O20S2 1118.4961, found 1118.4925 [M+H]
+ .
DOTAGlc2 (2b): Starting from the fully protected compound 17b
(0.683 g, 0.420 mmol) the title compound was obtained (0.356 g, 76%)
over two steps as a vitreous solid. 1H NMR (300 MHz, D2O, pH 7.0): d=
4.55 (d, J=9.9 Hz, 2H; H-1), 3.63 (appt, 2H; H-2), 3.69 (app t, 2H; H-3),
3.56 (dd, J=12.3, 2.1 Hz, 2H; H-4), 3.91 (app t, 2H; H-5), 3.47 (m, 4H;
H-6a, H-6b), 3.30 (m, 4H; C(O)NHCH2), 3.40 (m, 8H; NCH2,
NCH2CH2CH2), 1.87 (brm, 4H; NCH2CH2), 2.64 (m, 4H; SCH2CH2),
3.00 (t, J=6.6 Hz, 4H; SCH2), 3.82 (m, 2H; DOTA amide NCH2C(O)),
3.44 (s, 6H; DOTA acetate NCH2CO2
), 3.51, 3.20, 3.12, 2.80, 2.36, 2.23
(br, 8S2H; DOTA macrocycle NCH2);
13C NMR (75.6 MHz, D2O): d=
26.57, 36.42, 38.38, 38.99, 48.58, 48.78, 50.50, 52.15, 52.60, 56.44, 61.15,
69.77, 71.07, 72.30, 77.31, 79.92, 85.75 (C-1), 169.83, 172.85, 174.65,
178.82; MS (FAB+ , NBA): m/z (%): 1141 (9) [M+Na]+ , 1119 (6)
[M+H]+ ; HRMS (FAB+ , NBA): m/z : calcd for C44H81N9O20S2:
1119.5039, found 1119.4978 [M+H]+ .
DOTALac2 (2c): Starting from the fully protected compound 17c
(0.700 g, 0.314 mmol) the title compound was obtained (0.295 g, 65%)
over two steps as a vitreous solid: 1H NMR (300 MHz, D2O, pH 7.0): d=
4.42 (d, J=7.8 Hz, 2H; H-1), 3.52 (dd, J=10.2, 7.8 Hz, 2H; H-2), 3.63
(app t, 2H; H-3), 3.72 (dd, 2H; H-4), 3.98 (d, J=3.3 Hz, 2H; H-5), 3.70
(m, 4H; H-6a, H-6b), 4.55 (d, J=10.2 Hz, 2H; H-1’), 3.33 (app t, 2H; H-
2’), 3.64 (app t, 2H; H-3’), 3.72 (dd, 2H; H-4’), 3.88 (app t, 2H; H-5’),
3.72 (m, 4H; H-6a’, H-6b’), 3.30 (m, 4H; C(O)NHCH2), 3.40 (t, J=
6.0 Hz, 8H; NCH2, NCH2CH2CH2), 1.88 (brm, 4H; NCH2CH2), 2.60 (m,
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J=6.6 Hz, 4H; SCH2CH2), 2.96 (t, J=6.6 Hz, 4H; SCH2), 3.76 (m, 2H;
DOTA amide NCH2C(O)), 3.32 (s, 6H; DOTA acetate NCH2CO2
),
3.51, 3.20, 3.12, 2.80, 2.36, 2.23 (br, 16H; DOTA macrocycle NCH2);
(Gal unit: H-1–H-6b; Glc unit: H-1’–H-6b’); 13C NMR (75.6 MHz, D2O):
d=23.83, 26.40, 36.38, 38.31, 39.07, 48.60, 48.83, 48.98, 50.42, 52.19, 52.71,
56.43, 57.56, 60.44, 61.18, 68.69, 71.08, 72.03, 72.64, 75.51, 75.91, 78.37,
78.79, 85.53 (C-1’), 103.03 (C-1), 169.77, 172.92, 174.70, 178.80; MS
(FAB+ , NBA): m/z (%): 1443 (5) [M+H]+ , 1442 (7) [M]+ , 1343 (17),
1321 (5); HRMS (FAB+ , NBA): m/z : calcd for C56H100N9O30S2
1442.6018; found 1442.6017 [M+H]+ .
DOTAGal4 (3): Starting from the fully protected compound 16 (0.330 g,
0.118 mmol) the title compound was obtained (0.122 g, 53%) over two
steps as a vitreous solid. 1H NMR (300 MHz, D2O, pH 7.0): d=4.46 (d,
J=9.6 Hz, 4H; H-1), 3.49 (app t, 4H; H-2), 3.63 (dd, J=9.3, 3.0 Hz, 4H;
H-3), 3.70 (dd, 4H; H-4), 3.93 (app t, 4H; H-5), 3.70 (m, 8H; H-6a, H-
6b), 3.30 (m, 4H; C(O)NHCH2), 3.40 (m, 8H; NCH2CH2CH2NHC(O),
NCH2CH2CH2 NHC(O)), 1.93 (m, 4H; NCH2CH2CH2NHC(O)), 1.88 (m,
16H; NCH2CH2CH2NHC(O), NCH2CH2CH2 NHC(O)), 1.70 (m, 8H;
NCH2CH2CH2NHC(O)), 2.60 (m, 4H; SCH2CH2), 2.96 (app t, 4H;
SCH2), 3.74 (m, 2H; DOTA amide NCH2C(O)), 3.32 (s, 6H; DOTA ace-
tate NCH2CO2
), 3.51, 3.40, 3.12, 2.80, 2.36, 2.23 (br, 8S2H; DOTA mac-
rocycle NCH2);
13C NMR (75.6 MHz, D2O): d=24.87, 25.43, 26.64, 36.50,
36.89, 37.24, 38.52, 38.80, 48.68 (cluster of signals), 50.58, 52.08, 52.31,
56.31, 56.46, 56.95, 61.36, 68.93, 69.63, 74.05, 79.04, 86.24 (C-1), 169.83,
172.68, 174.42, 178.51; MS (FAB+ , NBA): m/z (%): 1999 (20) [M+K]+ ;
HRMS (FAB+ , NBA): m/z : calcd for C78H141N15O34S4K 1998.8285, found
1998.8325 [M+K]+ .
DOTAGal (1a): Starting from the fully protected compound 18a
(0.502 g, 0.486 mmol) the title compound was obtained (0.205 g, 60%)
over two steps as a vitreous solid. 1H NMR (300 MHz, D2O, pH 7.0): d=
4.50 (d, J=9.6 Hz, 1H; H-1), 3.55 (app t, J=9.6 Hz, 1H; H-2), 3.65 (dd,
J=9.3, 3.0 Hz, 1H; H-3), 3.74 (m, 1H; H-4), 3.97 (app t, J=3.3 Hz, 1H;
H-5), 3.70 (m, 2H; H-6a, H-6b), 3.46, 3.37 (m, 4H; NCH2, NCH2CH2),
2.59 (m, 2H; SCH2CH2), 2.99 (app t, 2H; SCH2), 3.81 (m, 2H; DOTA
amide NCH2C(O)), 3.44 (s, 6H; DOTA acetate NCH2CO2
), 3.51, 3.20,
3.12, 2.80, 2.36, 2.23 (br, 16H; DOTA macrocycle NCH2);
13C NMR
(75.6 MHz, D2O): d=26.36, 36.54, 38.28, 38.66, 39.25, 48.49 (cluster of
signals), 50.92, 51.97, 52.90 (cluster of signals), 56.01, 56.12, 56.54, 57.04,
58.79, 59.12, 61.32, 61.38, 68.96, 69.69, 74.05, 79.09, 86.15 (C-1), 170.04,
172.53, 174.60, 174.70, 174.79, 178.09, 180.16, 180.24; HRMS (FAB+ ,
NBA): m/z : calcd for C27H49N6O13S 697.3078, found 697.3046 [M+H]
+ .
DOTAGlc (1b): Starting from the fully protected compound 18b
(0.300 g, 0.290 mmol) the title compound was obtained (0.108 g, 53%)
over two steps as a vitreous solid. 1H NMR (300 MHz, D2O, pH 7.0): d=
4.50 (d, J=9.6 Hz, 1H; H-1), 3.55 (app t, J=9.6 Hz, 1H; H-2), 3.65 (dd,
J=9.3, 3.0 Hz, 1H; H-3), 3.74 (m, 1H; H-4), 3.97 (app t, J=3.3 Hz, 1H;
H-5), 3.70 (m, 2H; H-6a, H-6b), 3.46, 3.37 (m, 4H; NCH2, NCH2CH2),
2.59 (m, 2H; SCH2CH2), 2.99 (app t, 2H; SCH2), 3.81 (m, 2H; DOTA
amide NCH2C(O)), 3.44 (s, 6H; DOTA acetate NCH2CO2
), 3.51, 3.20,
3.12, 2.80, 2.36, 2.23 (br, 16H; DOTA macrocycle NCH2);
13C NMR
(75.6 MHz, D2O) 26.27, 36.59, 38.72, 48.57, 50.94, 52.02, 55.72, 56.23,
56.58, 61.14, 69.78, 72.38, 77.36, 80.02, 85.66 (C-1), 170.02, 172.56, 174.70,
177.65; HRMS (FAB+ , NBA): m/z : calcd for C27H49N6O13S, 697.3078,
found 697.3068 [M+H]+ .
DOTALac (1c): Starting from the fully protected compound 18c
(0.310 g, 0.234 mmol) the title compound was obtained (0.098 g, 49%)
over two steps as a vitreous solid.1H NMR (300 MHz, D2O, pH 7.0): d=
4.50 (d, J=9.6 Hz, 1H; H-1), 3.55 (app t, J=9.6 Hz, 1H; H-2), 3.65 (dd,
J=9.3, 3.0 Hz, 1H; H-3), 3.74 (m, 1H; H-4), 3.97 (app t, J=3.3 Hz, 1H;
H-5), 3.70 (m, 2H; H-6a, H-6b), 3.46, 3.37 (m, 4H; NCH2, NCH2CH2),
2.59 (m, 2H; SCH2CH2), 2.99 (app t, 2H; SCH2), 3.81 (m, 2H; DOTA
amide NCH2C(O)), 3.44 (s, 6H; DOTA acetate NCH2CO2
), 3.51, 3.20,
3.12, 2.80, 2.36, 2.23 (br, 16H; DOTA macrocycle NCH2);
13C NMR
(75.6 MHz, D2O, pH 7.0): d=26.19, 26.37, 27.61, 36.58, 38.70, 48.56,
50.94, 52.04, 56.13, 56.20, 56.54, 61.22, 61.35, 68.76, 69.02, 69.73, 71.15,
72.12, 72.70, 74.10, 75.53, 75.92, 78.32, 78.84, 79.13, 85.50, 86.19 (C-1’),
103.06 (C-1), 170.01, 172.58, 174.67, 174.73, 174.73, 178.16; HRMS
(FAB+ , NBA): m/z : calcd for C33H59N6O18S 859.3606, found 859.3644
[M+H]+ .
Preparation of LnIII–glycoconjugates for NMR : The LnIII–glycoconju-
gates were prepared by adding a slight excess (1.1 equiv) of an aqueous
solution of LnCl3 to an aqueous solution of the glycoconjugate. The so-
lution was slowly adjusted to pH 5 with aq. KOH and stirred at 70 8C for
8 h. The final pH was adjusted to 7 with KOH (aq) and any precipitate
was filtered off. The solution was concentrated and purified by gel filtra-
tion with Sephadex G10, eluting with water. The relevant fractions were
pooled and freeze dried to afford the LnIII complexes.
Preparation of GdIII–glycoconjugates for NMRD : The 1/T1 nuclear mag-
netic relaxation dispersion (NMRD) profiles of the water protons at 25,
37 and 60 8C were obtained on 2.52–4.63mm GdIII solutions. The concen-
tration of the GdIII solutions was determined by ICP. The concentration
of the DOTA-derivated glycoconjugates was determined from the pH-
potentiometric titration curves in the presence of a 50-fold excess of
CaCl2, with TMAOH. The solutions of the Gd
III–glycoconjugates were
prepared by adding appropriate quantities of the glycoconjugates to an
aqueous solution of gadolinium perchlorate (3–5% glycoconjugate
excess). The GdIII–glycoconjugate solutions were freeze dried and diluted
with 25mm phosphate buffer (pH 7.4). The GdIII concentrations were
verified by ICP measurement.
Appendix
NMRD : The measured proton relaxivities (normalized to 1mm GdIII con-
centration) contain both inner and outer sphere contributions as in Equa-
tion (1):
r1 ¼ rlis þ rlos ð1Þ
The inner sphere term is given by Equation (2), where q is the number of
inner sphere water molecules.
rlis ¼
1
1000
	 q
55:55
	 1
TH1mþtm
ð2Þ
The longitudinal relaxation rate of inner sphere protons, 1/TH1m is ex-
pressed in Equation (3)
1
TH1m
¼ 2
15

mo
4p
2 h2g 2Sg 2I
r 6GdH
SðSþ 1Þ

3td1H
1þ w 2I t 2d1H
þ 7td2H
1 þ w 2St 2d2H

ð3Þ
Here rGdH is the effective distance between the Gd
III electron spin and
the water protons, wI is the proton resonance frequency and tdiH is given
by Equation (4), where tR is the rotational correlation time of the Gd
III-
Hwater vector:
1
tdiH
¼ 1
tm
þ 1
tR
þ 1
T ie
i ¼ 1, 2 ð4Þ
The tR rotational correlation time is assumed to have simple exponential
temperature dependence with an ER activation energy, see Equation (5):
tR ¼ t 298R exp

ER
R

1
T
 1
298:15

ð5Þ
The electron spin relaxation rates, 1/T1e and 1/T2e for metal ions in so-
lution with S> 1=2 are mainly governed by a transient zero-field-splitting
mechanism (ZFS).[51] In Equations (6) and (7) D2 is the trace of the
square of the transient zero-field-splitting tensor, tv is the correlation
time for the modulation of the ZFS with the activation energy Ev, and ws
is the electron spin Larmor frequency as in Equation (8):

1
T1e
ZFS
¼ 1
25
D2tvf4SðSþ 1Þ3g

1
1 þ w 2S t 2V
þ 4
1 þ 4w 2S t 2V

ð6Þ

1
T2e
ZFS
¼ D2tv

5:26
1 þ 0:372w 2S t 2V
þ 7:18
1 þ 1:24wStv

ð7Þ
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tv ¼ t 298v exp

EV
R

1
T
 1
298:15

ð8Þ
The outer sphere contribution is described by Equation (9), where NA is
the Avogadro constant, and Jos is a spectral density function, see Equa-
tion (10):
rlos ¼
32NAp
405

m0
4p
2 h2g 2Sg 2I
aGdHDGdH
SðSþ 1Þ½3JosðwI, T1eÞ þ 7JosðwS,T2eÞ
ð9Þ
Josðw,T jeÞ ¼
Re
 1þ 1=4

iwtGdH þ tGdHT je
1=2
1þ

iwtGdH þ tGdHT je
1=2
þ 4=9

iwtGdH þ tGdHT je

þ 1=9

iwtGdH þ tGdHT je
3=2

j ¼ 1, 2
ð10Þ
A value of 3.6 V was used for aGdH. For the temperature dependence of
the diffusion coefficient for the diffusion of a water proton away from a
GdIII complex, DGdH, we assume a exponential temperature dependence,
with an activation energy EDGdH as in Equation (11):
DGdH ¼ D 298GdHexp

EDGdH
R

1
T
 1
298:15

ð11Þ
Acknowledgment
This work was performed within the framework of the EU COST Action
D18 “Lanthanide chemistry for diagnosis and therapy”. The work was
supported by the Foundation of Science and Technology (F.C.T.), Portu-
gal (project POCTI/QUI/47005/2002) and FEDER. J.P. Andr= would like
to acknowledge Prof. H. R. MYcke for the support he received during his
sabbatical leave. F. TGth and A. E. Merbach acknowledge the Swiss Na-
tional Science Foundation and the Swiss Federal Office for Education
and Science for financial support. The authors are grateful to LIszlG
Burai for his help in the NMRD measurements.
[1] A. Heppeler, S. Froidevaux, A. N. Eberle, H. R. Maecke, Curr. Med.
Chem. 2000, 7, 971–994.
[2] C. J. Anderson, M. J. Welch, Chem. Rev. 1999, 99, 2219–2234.
[3] W. A. Volkert, T. J. Hoffman, Chem. Rev. 1999, 99, 2269–2292.
[4] S. M. Qaim, Radiochim. Acta 2001, 89, 297–302.
[5] R. P. Junghans, D. Dobbs, M. W. Brechbiel, S. Mirzadeh, A. A. Rau-
bitschek, O. A. Gansow, T. A. Walmann, Cancer Res. 1993, 53,
5683–5689.
[6] S. W. J. Lamberts, A. J. Van der Lely, W. W. de Herder, L. Hofland,
New Engl. J. Med. 1996, 334, 246–254.
[7] P. Caravan, J. J. Ellison, T. J. McMurry, R. B. Lauffer, Chem. Rev.
1999, 99, 2293–2352.
[8] F. TGth, L. Helm, A. E. Merbach, Top. Curr. Chem. 2002, 221, 61–
101.
[9] S. Aime, C. Cabella, S. Colombatto, S. G. Crich, E. Gianolio, F. Mag-
gioni, J. Magn. Res. Imag. 2002, 16, 394–406.
[10] F. Cavagna, M. DaprZ, F. Maggioni, C. De Ha[n, E. Felder, Magn.
Reson. Med. 1991, 22, 329–333.
[11] H. S. -Willich, M. Brehm, C. L. J. Ewers, G. Michl, A. M. -Fahrnow,
O. Petrov, J. Platzek, B. Raduchel, D. S\lzle, Inorg. Chem. 1999, 38,
1134–1144.
[12] S. M. Rocklage, W. P. Cacheris, S. C. Quay, F. E. Hahn, K. N. Ray-
mond, Inorg. Chem. 1989, 28, 477–485.
[13] M. I. Papisov, A. Bogdanov, B. Schaffer, N. Nossif, T. Shen, R. Weis-
sleder, T. J. Brady, J. Magn. Magn. Mater. 1993, 122, 383–386.
[14] G. W. Kabalka, M. A. Davis, T. H. Moss, E. Buonocore, K. Hubner,
E. Holmberg, K. Maruyama, L. Huang, Magn. Res. Med. 1991, 19,
406–415.
[15] J. P. Andr=, F. TGth, H. Fischer, A. Seelig, H. R. MYcke, A. E. Mer-
bach, Chem. Eur. J. 1999, 5, 2977–2983.
[16] T. K. Dam, C. F. Brewer, Chem. Rev. 2002, 102, 387–429.
[17] H. Lis, N. Sharon, Chem. Rev. 1998, 98, 637–674.
[18] a) M. Mammen, S.-K. Choi, G. M. Whitesides, Angew. Chem. 1998,
110, 2908–2953; Angew. Chem. Int. Ed. 1998, 37, 2754–2794; b) J. J.
Lundquist, E. J. Toone, Chem. Rev. 2002, 102, 555–578.
[19] I. Vrasidas, S. Andr=, P. Valentini, C. Bock, M. Lensch, H. Kaltner,
R. M. J. Liskamp, H.-J. Gabius, R. J. Pieters, Org. Biomol. Chem.
2003, 1, 803–810.
[20] P. H. Weigel, J. H. N. Yik, Biochim. Biophys. Acta (General Subjects)
2002, 1572, 341–363.
[21] N. Yamazaki, S. Kojima, N. V. Bovin, S. Andr=, S. Gabius, H.-J.
Gabius, Adv. Drug Delivery Rev. 2000, 43, 225–244.
[22] G. Gregoriadis, Lancet 1981, 2, 241–246.
[23] K. A. Deal, M. E. Criste, M. J. Welsh, Nucl. Med. Biol. 1998, 25,
379–385.
[24] S. Ishibashi, R. E. Hammer, J. Herz, J. Biol. Chem. 1994, 269,
27803–27806.
[25] Y. Koyama, M. Ishikawa, A. Yeda, R. Sudo, S. Kojima, A. Suguna-
ka, Polym. J. 1993, 25, 355–361.
[26] D. R. Vera, R. Stadalnik, K. Krohn, J. Nucl. Med. 1985, 26, 1157–
1167.
[27] M. M. Alauddin, A. Y. Louie, A. Shahinian, T. J. Meade, P. S. Conti,
Nucl. Med. Biol. 2003, 30, 261–265.
[28] S. D. Colquhoum, C. A. Conelly, D. R. Vera, J. Nucl. Med. 2001, 42,
110–116.
[29] K. Miki, K. Kubota, Y. Inoue, D. R. Vera, M. Makuuchi, J. Nucl.
Med. 2001, 42, 733–737.
[30] N. Shuke, H. O. Kizaki, S. Kino, J. Sato, Y. Ishikawa, C. L. Zhao, S.
Kineya, N. Watabane, K. Yokoama, T. Aburano, J. Nucl. Med. 2003,
44, 475–482.
[31] B. K. Schaffer, C. Linker, M. Papisov, E. Tsai, N. Nossiff, T. Shibata,
A. Bogdanov, T. J. Brady, R. Weissleder, Magn. Reson. Imaging
1993, 11, 411–417.
[32] P. Reimer, R. Weissleder, A. S. Lee, S. Buettner, J. Wittenberg, T. J.
Brady, Radiology 1991, 178, 769–774.
[33] P. Reimer, R. Weissleder, T. J. Brady, Radiology 1992, 182, 1161–
1167.
[34] B. Gallez, V. Lacour, R. Demeure, R. Debuyst, F. Dejehet, J. L. De-
keyser, P. Dumont, Magn. Reson. Imaging 1994, 12, 61–69.
[35] D. R. Vera, M. H. Buonocore, E. R. Wisner, R. W. Katzberg, R. C.
Stadalnik, Acad. Radiol. 1995, 2, 497–506.
[36] A. Bianchi, L. Calabi, F. Corana, S. Fontana, P. Losi, A. Maiocchi,
L. Paleari, B. Valtancoli, Coord. Chem. Rev. 2000, 204, 309–393.
[37] a) W. B. Turnbull, J. F. Stoddart, Rev. Mol. Biotech. 2002, 90, 231–
255; b) D. Zanini, R. Roy, J. Org. Chem. 1996, 61, 7348–7354.
[38] C. F. G. C. Geraldes, A. D. Sherry, M. P. M. Marques, M. C. Alpoim,
S. Cortes, J. Chem. Soc. Perkin Trans. 2 1991, 137–146.
[39] J. A. Peters, E. Zitha-Bovens, D. Corsi, C. F. G. C. Geraldes, “Struc-
ture and Dynamics of Gadolinium-Based Contrast Agents” in The
Chemistry of Contrast Agents in Medical Magnetic Resonance Imag-
ing (Eds.: F. TGth, A. E. Merbach), Wiley, Chichester, 2001, p. 315–
381.
[40] S. Aime, M. Botta, G. Ermondi, Inorg. Chem. 1992, 31, 4291–4299.
[41] S. Aime, M. Botta, M. Fasano, M. P. M. Marques, C. F. G. C. Ger-
aldes, D. Pubanz, A. E. Merbach, Inorg. Chem. 1997, 36, 2059–2068.
[42] S. Aime, M. Botta, E. Garino, S. G. Crich, G. Giovenzana, R. Pa-
gliarin, G. Palmisano, M. Sisti, Chem. Eur. J. 2000, 6, 2609–2617.
[43] F. TGth, L. Helm, A. E. Merbach, “Relaxivity of Gadolinium(iii)
Complexes: Theory and Mechanism” in The Chemistry of Contrast
Agents in Medical Magnetic Resonance Imaging (Eds.: F. TGth,
A. E. Merbach) Wiley, Chichester, 2001, p. 45–119.
[44] D. H. Powell, O. M. Ni Dhubhghaill, D. Pubanz, L. Helm, Y. S. Leb-
edev, W. Schlaepfer, A. E. Merbach, J. Am. Chem. Soc. 1996, 118,
9333–9346.
[45] A. D. Sherry, R. D. Brown III, C. F. G. C. Geraldes, S. H. Koenig,
K.-T. Kuan, M. Spiller, Inorg. Chem. 1989, 28, 620–622.
[46] R. B. Clarkson, A. I. Smirnov, T. I. Smirnova, R. L. Belford, “Multi-
frequency and High-Frequency EPR Methods in Contrast Agent
Research: Examples from Gd3+ Chelates” in The Chemistry of Con-
Chem. Eur. J. 2004, 10, 5804 – 5816 www.chemeurj.org N 2004 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim 5815
DOTA–Glycoconjugates 5804 – 5816
trast Agents in Medical Magnetic Resonance Imaging (Eds.: F. TGth,
A. E. Merbach), Wiley, Chichester, 2001, p. 383–415.
[47] S. Rast, A. Borel, L. Helm, E. Belorizky, P. H. Fries, A. E. Merbach,
J. Am. Chem. Soc. 2001, 123, 2637–2644; b) S. Rast, P. H. Fries, E.
Belorizky, A. Borel, L. Helm, A. E. Merbach, J. Chem. Phys. 2001,
115, 7554–7563.
[48] Unpublished results.
[49] A. D. Nunn, K. E. Liner, M. F. Tweedle, Q. J. Nucl. Med. 1997, 41,
155.
[50] V. Jacques, J. F. Desreux, in New Classes of MRI Contrast Agents in
Topics in Current Chemistry, Vol. 221: Contrast Agents I. Magnetic
Resonance Imaging (Ed. W. Krause) Springer, Berlin, 2002, p. 123–
164.
[51] a) A. D. McLachlan, Proc. R. Soc. London, Proc. R. Soc. London
Ser. A 1964, 280, 271; b) D. H. Powell, A. E. Merbach, G. GonzIlez,
E. Br\cher, K. Micskei, M. F. Ottaviani, K. Kçhler, A. von Zelew-
sky, O. Y. Grinberg, Y. S. Lebedev, Helv. Chim. Acta 1993, 76, 2129–
2146.
[52] a) Y. C. Lee, R. R. Townsend, M. R. Hardy, J. Lçnngren, J. Arnarp,
M. Haraldsson, H. Lçnn, J. Biol. Chem. 1983, 258, 199–202; b) R. T.
Lee, Y. C. Lee, Biochem. Biophys. Res. Commun. 1988, 155, 1444–
1451; c) E. A. L. Biessen, H. Broxterman, J. H. Van Boom, T. J.
Van Berkel, J. Med. Chem. 1995, 38, 1846–1852.
Received: July 8, 2004
Published online: October 7, 2004
N 2004 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chemeurj.org Chem. Eur. J. 2004, 10, 5804 – 58165816
FULL PAPER J. P. Andr=, J. A. Martins et al.
